Nutra Pharma Corp (NPHC) FCF Margin (2010 - 2026)

Nutra Pharma has disclosed FCF Margin across 17 years of filings, most recently posting 728.96% for Q2 2026.

• In Q2 2026, FCF Margin fell 38783.0% year-over-year to 728.96%; the TTM figure through Jun 2026 stood at 652.68% (down 37410.0% YoY), while the FY2025 annual figure was 461.94%, down 28982.0% from the prior year.
• FCF Margin came in at 728.96% for Q2 2026 at Nutra Pharma, up from 1203.08% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 25.43% in Q3 2024 to a low of 2298.33% in Q1 2022.
• Average FCF Margin over 5 years is 551.52%, with a median of 376.49% recorded in 2025.
• Year-over-year, FCF Margin soared 212817 bps in 2023 and tumbled 62036 bps in 2026.
• Over 5 years, FCF Margin stood at 68.41% in 2022, then sank by 479 bps to 395.96% in 2023, then jumped by 45 bps to 217.67% in 2024, then sank by 250 bps to 761.56% in 2025, then gained by 4 bps to 728.96% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 728.96% in Q2 2026, 1203.08% in Q1 2026, and 761.56% in Q4 2025.